<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84952785475</prism:url><dc:identifier>SCOPUS_ID:84952785475</dc:identifier><eid>2-s2.0-84952785475</eid><pubmed-id>26726793</pubmed-id><prism:doi>10.3109/03009742.2015.1105290</prism:doi><dc:title>Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>5</citedby-count><prism:publicationName>Scandinavian Journal of Rheumatology</prism:publicationName><dc:publisher>Taylor and Francis Ltdhealthcare.enquiries@informa.com</dc:publisher><source-id>19781</source-id><prism:issn>15027732 03009742</prism:issn><prism:volume>45</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:startingPage>347</prism:startingPage><prism:endingPage>355</prism:endingPage><prism:pageRange>347-355</prism:pageRange><prism:coverDate>2016-09-02</prism:coverDate><openaccess>0</openaccess><openaccessFlag>false</openaccessFlag><dc:creator><author seq="1" auid="35099195400"><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>K.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35099195400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2016 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation.</publishercopyright><ce:para>Objectives: The mechanism by which methotrexate (MTX) improves glucose homeostasis in patients with rheumatoid (RA) and psoriatic arthritis (PsA) remains undetermined. Animal studies indicate a role for intracellular accumulation of 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranosyl 5ʹ-monophosphate (ZMP) but this has not been directly demonstrated in humans. We explored whether accumulation of ZMP is associated with improvements in glucose homeostasis during MTX therapy. Method: MTX-naïve, non-diabetic RA (n = 16) and PsA (n = 10) patients received uninterrupted MTX treatment for 6 months. To evaluate whether ZMP accumulated during MTX therapy, we measured the concentration of ZMP in erythrocytes and the concentration of its dephosphorylated derivative 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) in urine using liquid chromatography mass spectrometry (LC-MS/MS). To assess glucose homeostasis, we determined the concentration of glycated haemoglobin (HbA1c) and homeostasis model assessment of insulin resistance [HOMA-IR: fasting glucose (mmol/L) × fasting insulin (μU/mL)/22.5]. Results: Erythrocyte ZMP and urinary AICAR concentrations did not increase during 6 months of MTX therapy. HbA1c concentration was reduced from 5.80 ± 0.29% at baseline to 5.51 ± 0.32% at 6 months (p &lt; 0.001), while HOMA-IR remained unaltered. Reduction in HbA1c concentration was not associated with increased ZMP or AICAR concentrations. Conclusions: MTX therapy probably does not produce a chronic increase in erythrocyte ZMP or urinary AICAR concentrations. Collectively, our data do not support the hypothesis that MTX improves glucose homeostasis through chronic accumulation of ZMP.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84952785475" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84952785475&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84952785475&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60026552" href="https://api.elsevier.com/content/affiliation/affiliation_id/60026552"><affilname>University of Ljubljana Faculty of Medicine, Institute of Pathophysiology</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"><affilname>Univerzitetni Klinični Center Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60012797" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012797"><affilname>Deutsche Sporthochschule Köln</affilname><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation id="60012311" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012311"><affilname>Karolinska Institutet</affilname><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><authors><author seq="1" auid="35099195400"><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>K.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35099195400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="2" auid="24485220600"><ce:initials>S.</ce:initials><ce:indexed-name>Pirkmajer S.</ce:indexed-name><ce:surname>Pirkmajer</ce:surname><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Pirkmajer S.</ce:indexed-name><ce:surname>Pirkmajer</ce:surname><ce:given-name>S.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24485220600</author-url><affiliation id="60026552" href="https://api.elsevier.com/content/affiliation/affiliation_id/60026552"/></author><author seq="3" auid="6701759399"><ce:initials>M.</ce:initials><ce:indexed-name>Thevis M.</ce:indexed-name><ce:surname>Thevis</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Thevis M.</ce:indexed-name><ce:surname>Thevis</ce:surname><ce:given-name>M.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6701759399</author-url><affiliation id="60012797" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012797"/></author><author seq="4" auid="35604752100"><ce:initials>A.</ce:initials><ce:indexed-name>Thomas A.</ce:indexed-name><ce:surname>Thomas</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Thomas A.</ce:indexed-name><ce:surname>Thomas</ce:surname><ce:given-name>A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35604752100</author-url><affiliation id="60012797" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012797"/></author><author seq="5" auid="6701703534"><ce:initials>S.</ce:initials><ce:indexed-name>Praprotnik S.</ce:indexed-name><ce:surname>Praprotnik</ce:surname><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Praprotnik S.</ce:indexed-name><ce:surname>Praprotnik</ce:surname><ce:given-name>S.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6701703534</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="6" auid="6506634484"><ce:initials>A.</ce:initials><ce:indexed-name>Hocevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Hočevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><ce:given-name>A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6506634484</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="7" auid="23499140000"><ce:initials>Ž.</ce:initials><ce:indexed-name>Rotar Z.</ce:indexed-name><ce:surname>Rotar</ce:surname><preferred-name><ce:initials/><ce:indexed-name>Rotar</ce:indexed-name><ce:surname>Rotar</ce:surname><ce:given-name/></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23499140000</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="8" auid="23003996400"><ce:initials>N.</ce:initials><ce:indexed-name>Gaspersic N.</ce:indexed-name><ce:surname>Gašperšič</ce:surname><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>Gašperšič N.</ce:indexed-name><ce:surname>Gašperšič</ce:surname><ce:given-name>N.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23003996400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="9" auid="55934770900"><ce:initials>S.</ce:initials><ce:indexed-name>Sodin-Semrl S.</ce:indexed-name><ce:surname>Sodin-Šemrl</ce:surname><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Sodin-Šemrl S.</ce:indexed-name><ce:surname>Sodin-Šemrl</ce:surname><ce:given-name>S.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55934770900</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="10" auid="6507417859"><ce:initials>J.</ce:initials><ce:indexed-name>Zibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Žibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><ce:given-name>J.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6507417859</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="11" auid="24765108800"><ce:initials>J.</ce:initials><ce:indexed-name>Omersel J.</ce:indexed-name><ce:surname>Omersel</ce:surname><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Omersel J.</ce:indexed-name><ce:surname>Omersel</ce:surname><ce:given-name>J.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24765108800</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="12" auid="7004676576"><ce:initials>A.</ce:initials><ce:indexed-name>Chibalin A.</ce:indexed-name><ce:surname>Chibalin</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Chibalin A.</ce:indexed-name><ce:surname>Chibalin</ce:surname><ce:given-name>A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004676576</author-url><affiliation id="60012311" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012311"/></author><author seq="13" auid="7004670720"><ce:initials>M.</ce:initials><ce:indexed-name>Tomsic M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Tomšič M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><ce:given-name>M.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004670720</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="14" auid="6602786082"><ce:initials>A.</ce:initials><ce:indexed-name>Ambrozic A.</ce:indexed-name><ce:surname>Ambrožič</ce:surname><ce:given-name>Aleš</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Ambrožič A.</ce:indexed-name><ce:surname>Ambrožič</ce:surname><ce:given-name>Aleš</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6602786082</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author></authors><language xml:lang="eng"/><authkeywords/><idxterms><mainterm weight="b" candidate="n">Adult</mainterm><mainterm weight="b" candidate="n">Aged</mainterm><mainterm weight="b" candidate="n">Aminoimidazole Carboxamide</mainterm><mainterm weight="b" candidate="n">Antirheumatic Agents</mainterm><mainterm weight="b" candidate="n">Arthritis, Psoriatic</mainterm><mainterm weight="b" candidate="n">Arthritis, Rheumatoid</mainterm><mainterm weight="b" candidate="n">Blood Glucose</mainterm><mainterm weight="b" candidate="n">Chromatography, Liquid</mainterm><mainterm weight="b" candidate="n">Erythrocytes</mainterm><mainterm weight="b" candidate="n">Female</mainterm><mainterm weight="b" candidate="n">Hemoglobin A, Glycosylated</mainterm><mainterm weight="b" candidate="n">Humans</mainterm><mainterm weight="b" candidate="n">Insulin</mainterm><mainterm weight="b" candidate="n">Insulin Resistance</mainterm><mainterm weight="b" candidate="n">Male</mainterm><mainterm weight="b" candidate="n">Methotrexate</mainterm><mainterm weight="b" candidate="n">Middle Aged</mainterm><mainterm weight="b" candidate="n">Prospective Studies</mainterm><mainterm weight="b" candidate="n">Ribonucleotides</mainterm><mainterm weight="b" candidate="n">Tandem Mass Spectrometry</mainterm></idxterms><subject-areas><subject-area code="2745" abbrev="MEDI">Rheumatology</subject-area><subject-area code="2723" abbrev="MEDI">Immunology and Allergy</subject-area><subject-area code="2403" abbrev="IMMU">Immunology</subject-area></subject-areas><item xmlns=""><ait:process-info><ait:date-delivered year="2019" month="06" day="03" timestamp="2019-06-03T23:15:17.000017-04:00"/><ait:date-sort year="2016" month="09" day="02"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2017 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.3109/03009742.2015.1105290</ce:doi><itemid idtype="PUI">607520907</itemid><itemid idtype="CABS">2016006419</itemid><itemid idtype="CAR-ID">643821798</itemid><itemid idtype="EMBASE">20160012607</itemid><itemid idtype="MEDL">26726793</itemid><itemid idtype="MOSYEA">2016003051</itemid><itemid idtype="REAXYSCAR">2016050293</itemid><itemid idtype="SCP">84952785475</itemid><itemid idtype="SGR">84952785475</itemid><itemid idtype="PUIsecondary">614316352</itemid></itemidlist><history><date-created year="2016" month="09" day="09" timestamp="BST 15:56:01"/></history><dbcollection>CABS</dbcollection><dbcollection>EMBASE</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>MOSYEA</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis</titletext></citation-title><author-group><author auid="35099195400" seq="1" type="auth"><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>K.</ce:given-name></preferred-name></author><author auid="6701703534" seq="5" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Praprotnik S.</ce:indexed-name><ce:surname>Praprotnik</ce:surname><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Praprotnik S.</ce:indexed-name><ce:surname>Praprotnik</ce:surname><ce:given-name>S.</ce:given-name></preferred-name></author><author auid="6506634484" seq="6" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Hocevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Hočevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><ce:given-name>A.</ce:given-name></preferred-name></author><author auid="23499140000" seq="7" type="auth"><ce:initials>Ž.</ce:initials><ce:indexed-name>Rotar Z.</ce:indexed-name><ce:surname>Rotar</ce:surname><preferred-name><ce:initials/><ce:indexed-name>Rotar</ce:indexed-name><ce:surname>Rotar</ce:surname><ce:given-name/></preferred-name></author><author auid="23003996400" seq="8" type="auth"><ce:initials>N.</ce:initials><ce:indexed-name>Gaspersic N.</ce:indexed-name><ce:surname>Gašperšič</ce:surname><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>Gašperšič N.</ce:indexed-name><ce:surname>Gašperšič</ce:surname><ce:given-name>N.</ce:given-name></preferred-name></author><author auid="55934770900" seq="9" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Sodin-Semrl S.</ce:indexed-name><ce:surname>Sodin-Šemrl</ce:surname><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Sodin-Šemrl S.</ce:indexed-name><ce:surname>Sodin-Šemrl</ce:surname><ce:given-name>S.</ce:given-name></preferred-name></author><author auid="7004670720" seq="13" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Tomsic M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Tomšič M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><ce:given-name>M.</ce:given-name></preferred-name></author><author auid="6602786082" seq="14" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Ambrozic A.</ce:indexed-name><ce:surname>Ambrožič</ce:surname><ce:given-name>Aleš</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Ambrožič A.</ce:indexed-name><ce:surname>Ambrožič</ce:surname><ce:given-name>Aleš</ce:given-name></preferred-name></author><affiliation afid="60021479" dptid="100302769" country="svn"><organization>Department of Rheumatology</organization><organization>University Medical Centre Ljubljana</organization><affiliation-id afid="60021479" dptid="100302769"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="24485220600" seq="2" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Pirkmajer S.</ce:indexed-name><ce:surname>Pirkmajer</ce:surname><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Pirkmajer S.</ce:indexed-name><ce:surname>Pirkmajer</ce:surname><ce:given-name>S.</ce:given-name></preferred-name></author><affiliation afid="60026552" country="svn"><organization>Institute of Pathophysiology</organization><organization>Faculty of Medicine</organization><organization>University of Ljubljana</organization><affiliation-id afid="60026552"/><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="6701759399" seq="3" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Thevis M.</ce:indexed-name><ce:surname>Thevis</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Thevis M.</ce:indexed-name><ce:surname>Thevis</ce:surname><ce:given-name>M.</ce:given-name></preferred-name></author><author auid="35604752100" seq="4" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Thomas A.</ce:indexed-name><ce:surname>Thomas</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Thomas A.</ce:indexed-name><ce:surname>Thomas</ce:surname><ce:given-name>A.</ce:given-name></preferred-name></author><affiliation afid="60012797" dptid="103678599" country="deu"><organization>Institute of Biochemistry</organization><organization>Centre for Preventive Doping Research</organization><organization>German Sport University Cologne</organization><affiliation-id afid="60012797" dptid="103678599"/><country>Germany</country></affiliation></author-group><author-group><author auid="6507417859" seq="10" type="auth"><ce:initials>J.</ce:initials><ce:indexed-name>Zibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Žibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><ce:given-name>J.</ce:given-name></preferred-name></author><affiliation afid="60031106" dptid="112933932" country="svn"><organization>Faculty of Health Sciences</organization><organization>University of Ljubljana</organization><affiliation-id afid="60031106" dptid="112933932"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="24765108800" seq="11" type="auth"><ce:initials>J.</ce:initials><ce:indexed-name>Omersel J.</ce:indexed-name><ce:surname>Omersel</ce:surname><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Omersel J.</ce:indexed-name><ce:surname>Omersel</ce:surname><ce:given-name>J.</ce:given-name></preferred-name></author><affiliation afid="60031106" dptid="104580650" country="svn"><organization>Faculty of Pharmacy</organization><organization>University of Ljubljana</organization><affiliation-id afid="60031106" dptid="104580650"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="7004676576" seq="12" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Chibalin A.</ce:indexed-name><ce:surname>Chibalin</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Chibalin A.</ce:indexed-name><ce:surname>Chibalin</ce:surname><ce:given-name>A.</ce:given-name></preferred-name></author><affiliation afid="60012311" dptid="103649507" country="swe"><organization>Department of Molecular Medicine and Surgery</organization><organization>Integrative Physiology</organization><organization>Karolinska Institutet</organization><city>Stockholm</city><affiliation-id afid="60012311" dptid="103649507"/><country>Sweden</country></affiliation></author-group><correspondence><person><ce:initials>A.</ce:initials><ce:indexed-name>Ambrozic A.</ce:indexed-name><ce:surname>Ambrožič</ce:surname><ce:given-name>Aleš</ce:given-name></person><affiliation country="svn"><organization>Department of Rheumatology</organization><organization>University Medical Centre Ljubljana</organization><address-part>Vodnikova c. 62</address-part><city>Ljubljana</city><postal-code>1000</postal-code><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2016 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation.</publishercopyright><ce:para>Objectives: The mechanism by which methotrexate (MTX) improves glucose homeostasis in patients with rheumatoid (RA) and psoriatic arthritis (PsA) remains undetermined. Animal studies indicate a role for intracellular accumulation of 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranosyl 5ʹ-monophosphate (ZMP) but this has not been directly demonstrated in humans. We explored whether accumulation of ZMP is associated with improvements in glucose homeostasis during MTX therapy. Method: MTX-naïve, non-diabetic RA (n = 16) and PsA (n = 10) patients received uninterrupted MTX treatment for 6 months. To evaluate whether ZMP accumulated during MTX therapy, we measured the concentration of ZMP in erythrocytes and the concentration of its dephosphorylated derivative 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) in urine using liquid chromatography mass spectrometry (LC-MS/MS). To assess glucose homeostasis, we determined the concentration of glycated haemoglobin (HbA1c) and homeostasis model assessment of insulin resistance [HOMA-IR: fasting glucose (mmol/L) × fasting insulin (μU/mL)/22.5]. Results: Erythrocyte ZMP and urinary AICAR concentrations did not increase during 6 months of MTX therapy. HbA1c concentration was reduced from 5.80 ± 0.29% at baseline to 5.51 ± 0.32% at 6 months (p &lt; 0.001), while HOMA-IR remained unaltered. Reduction in HbA1c concentration was not associated with increased ZMP or AICAR concentrations. Conclusions: MTX therapy probably does not produce a chronic increase in erythrocyte ZMP or urinary AICAR concentrations. Collectively, our data do not support the hypothesis that MTX improves glucose homeostasis through chronic accumulation of ZMP.</ce:para></abstract></abstracts><source srcid="19781" type="j" country="gbr"><sourcetitle>Scandinavian Journal of Rheumatology</sourcetitle><sourcetitle-abbrev>Scand. J. Rheumatol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Scandinavian Journal of Rheumatology</translated-sourcetitle><issn type="electronic">15027732</issn><issn type="print">03009742</issn><codencode>SJRHA</codencode><volisspag><voliss volume="45" issue="5"/><pagerange first="347" last="355"/></volisspag><publicationyear first="2016"/><publicationdate><year>2016</year><month>09</month><day>02</day><date-text xfab-added="true">2 September 2016</date-text></publicationdate><publisher><publishername>Taylor and Francis Ltd</publishername><ce:e-address type="email">healthcare.enquiries@informa.com</ce:e-address></publisher></source><enhancement><classificationgroup><classifications type="CABSCLASS"><classification> <classification-code>86.8.5.2</classification-code> <classification-description>IMMUNOLOGY AND INFECTIOUS DISEASES; IMMUNE RESPONSE DISORDERS; Autoimmunity; Human studies</classification-description> </classification><classification> <classification-code>86.8.5.4</classification-code> <classification-description>IMMUNOLOGY AND INFECTIOUS DISEASES; IMMUNE RESPONSE DISORDERS; Autoimmunity; Diagnosis and therapy</classification-description> </classification></classifications><classifications type="EMCLASS"><classification> <classification-code>30</classification-code> <classification-description>Clinical and Experimental Pharmacology</classification-description> </classification><classification> <classification-code>31</classification-code> <classification-description>Arthritis and Rheumatism</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification><classification> <classification-code>38</classification-code> <classification-description>Adverse Reactions Titles</classification-description> </classification></classifications><classifications type="ASJC"><classification>2745</classification><classification>2723</classification><classification>2403</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification><classification>IMMU</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>5 amino 4 imidazolecarboxamide riboside</chemical-name><cas-registry-number>2627-69-2</cas-registry-number></chemical><chemical><chemical-name>C reactive protein</chemical-name><cas-registry-number>9007-41-4</cas-registry-number></chemical><chemical><chemical-name>creatinine</chemical-name><cas-registry-number>19230-81-0</cas-registry-number><cas-registry-number>60-27-5</cas-registry-number></chemical><chemical><chemical-name>folic acid</chemical-name><cas-registry-number>59-30-3</cas-registry-number><cas-registry-number>6484-89-5</cas-registry-number></chemical><chemical><chemical-name>glucose</chemical-name><cas-registry-number>50-99-7</cas-registry-number><cas-registry-number>84778-64-3</cas-registry-number></chemical><chemical><chemical-name>hemoglobin A1c</chemical-name><cas-registry-number>62572-11-6</cas-registry-number></chemical><chemical><chemical-name>insulin</chemical-name><cas-registry-number>9004-10-8</cas-registry-number></chemical><chemical><chemical-name>methotrexate</chemical-name><cas-registry-number>15475-56-6</cas-registry-number><cas-registry-number>59-05-2</cas-registry-number><cas-registry-number>7413-34-5</cas-registry-number></chemical><chemical><chemical-name>methylprednisolone</chemical-name><cas-registry-number>6923-42-8</cas-registry-number><cas-registry-number>83-43-2</cas-registry-number></chemical><chemical><chemical-name>urate</chemical-name><cas-registry-number>1198-77-2</cas-registry-number><cas-registry-number>3106-08-9</cas-registry-number><cas-registry-number>59216-10-3</cas-registry-number></chemical><chemical><chemical-name>5 amino 4 imidazolecarboxamide</chemical-name><cas-registry-number>360-97-4</cas-registry-number></chemical><chemical><chemical-name>glycosylated hemoglobin</chemical-name><cas-registry-number>9062-63-9</cas-registry-number></chemical></chemicals><chemicals source="nlm"><chemical><chemical-name>AICA ribonucleotide</chemical-name></chemical><chemical><chemical-name>Aminoimidazole Carboxamide</chemical-name></chemical><chemical><chemical-name>Antirheumatic Agents</chemical-name></chemical><chemical><chemical-name>Blood Glucose</chemical-name></chemical><chemical><chemical-name>Hemoglobin A, Glycosylated</chemical-name></chemical><chemical><chemical-name>hemoglobin A1c protein, human</chemical-name></chemical><chemical><chemical-name>Insulin</chemical-name></chemical><chemical><chemical-name>Methotrexate</chemical-name></chemical><chemical><chemical-name>Ribonucleotides</chemical-name></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="26"><reference id="1"><ref-info><ref-title><ref-titletext>Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">73349127171</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.E.</ce:initials><ce:indexed-name>Toms T.E.</ce:indexed-name><ce:surname>Toms</ce:surname></author><author seq="2"><ce:initials>V.F.</ce:initials><ce:indexed-name>Panoulas V.F.</ce:indexed-name><ce:surname>Panoulas</ce:surname></author><author seq="3"><ce:initials>H.</ce:initials><ce:indexed-name>John H.</ce:indexed-name><ce:surname>John</ce:surname></author><author seq="4"><ce:initials>K.M.</ce:initials><ce:indexed-name>Douglas K.M.</ce:indexed-name><ce:surname>Douglas</ce:surname></author><author seq="5"><ce:initials>G.D.</ce:initials><ce:indexed-name>Kitas G.D.</ce:indexed-name><ce:surname>Kitas</ce:surname></author></ref-authors><ref-sourcetitle>Arthritis Res Ther</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="11"/><pagerange first="R110"/></ref-volisspag></ref-info><ref-fulltext>T.E.Toms, V.F.Panoulas, H.John, K.M.Douglas, G.D.Kitas Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009;11:R110.</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84905034316</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.C.</ce:initials><ce:indexed-name>de Rotte M.C.</ce:indexed-name><ce:surname>de Rotte</ce:surname></author><author seq="2"><ce:initials>P.H.</ce:initials><ce:indexed-name>de Jong P.H.</ce:indexed-name><ce:surname>de Jong</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>den Boer E.</ce:indexed-name><ce:surname>den Boer</ce:surname></author><author seq="4"><ce:initials>S.M.</ce:initials><ce:indexed-name>Pluijm S.M.</ce:indexed-name><ce:surname>Pluijm</ce:surname></author><author seq="5"><ce:initials>B.</ce:initials><ce:indexed-name>Ozcan B.</ce:indexed-name><ce:surname>Özcan</ce:surname></author><author seq="6"><ce:initials>A.E.</ce:initials><ce:indexed-name>Weel A.E.</ce:indexed-name><ce:surname>Weel</ce:surname></author></ref-authors><ref-sourcetitle>Arthritis Rheumatol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="66"/><pagerange first="2026" last="2036"/></ref-volisspag></ref-info><ref-fulltext>M.C.de Rotte, P.H.de Jong, E.den Boer, S.M.Pluijm, B.Özcan, A.E.Weel, et al. Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis. Arthritis Rheumatol 2014;66:2026–36.</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79959426992</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.H.</ce:initials><ce:indexed-name>Solomon D.H.</ce:indexed-name><ce:surname>Solomon</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Massarotti E.</ce:indexed-name><ce:surname>Massarotti</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Garg R.</ce:indexed-name><ce:surname>Garg</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Liu J.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Canning C.</ce:indexed-name><ce:surname>Canning</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Schneeweiss S.</ce:indexed-name><ce:surname>Schneeweiss</ce:surname></author></ref-authors><ref-sourcetitle>JAMA</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="305"/><pagerange first="2525" last="2531"/></ref-volisspag></ref-info><ref-fulltext>D.H.Solomon, E.Massarotti, R.Garg, J.Liu, C.Canning, S.Schneeweiss. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011;305:2525–31.</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0027139914</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.N.</ce:initials><ce:indexed-name>Cronstein B.N.</ce:indexed-name><ce:surname>Cronstein</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Naime D.</ce:indexed-name><ce:surname>Naime</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Ostad E.</ce:indexed-name><ce:surname>Ostad</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Invest</ref-sourcetitle><ref-publicationyear first="1993"/><ref-volisspag><voliss volume="92"/><pagerange first="2675" last="2682"/></ref-volisspag></ref-info><ref-fulltext>B.N.Cronstein, D.Naime, E.Ostad. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675–82.</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85047689953</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.M.</ce:initials><ce:indexed-name>Corton J.M.</ce:indexed-name><ce:surname>Corton</ce:surname></author><author seq="2"><ce:initials>J.G.</ce:initials><ce:indexed-name>Gillespie J.G.</ce:indexed-name><ce:surname>Gillespie</ce:surname></author><author seq="3"><ce:initials>S.A.</ce:initials><ce:indexed-name>Hawley S.A.</ce:indexed-name><ce:surname>Hawley</ce:surname></author><author seq="4"><ce:initials>D.G.</ce:initials><ce:indexed-name>Hardie D.G.</ce:indexed-name><ce:surname>Hardie</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Biochem</ref-sourcetitle><ref-publicationyear first="1995"/><ref-volisspag><voliss volume="229"/><pagerange first="558" last="565"/></ref-volisspag></ref-info><ref-fulltext>J.M.Corton, J.G.Gillespie, S.A.Hawley, D.G.Hardie. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558–65.</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>AMPK: a target for drugs and natural products with effects on both diabetes and cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84883709817</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.G.</ce:initials><ce:indexed-name>Hardie D.G.</ce:indexed-name><ce:surname>Hardie</ce:surname></author></ref-authors><ref-sourcetitle>Diabetes</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="62"/><pagerange first="2164" last="2172"/></ref-volisspag></ref-info><ref-fulltext>D.G.Hardie. AMPK:a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013;62:2164–72.</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>AMP-activated protein kinase signaling in metabolic regulation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33745815985</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.C.</ce:initials><ce:indexed-name>Long Y.C.</ce:indexed-name><ce:surname>Long</ce:surname></author><author seq="2"><ce:initials>J.R.</ce:initials><ce:indexed-name>Zierath J.R.</ce:indexed-name><ce:surname>Zierath</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Invest</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="116"/><pagerange first="1776" last="1783"/></ref-volisspag></ref-info><ref-fulltext>Y.C.Long, J.R.Zierath. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006;116:1776–83.</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84921897035</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Pirkmajer S.</ce:indexed-name><ce:surname>Pirkmajer</ce:surname></author><author seq="2"><ce:initials>S.S.</ce:initials><ce:indexed-name>Kulkarni S.S.</ce:indexed-name><ce:surname>Kulkarni</ce:surname></author><author seq="3"><ce:initials>R.Z.</ce:initials><ce:indexed-name>Tom R.Z.</ce:indexed-name><ce:surname>Tom</ce:surname></author><author seq="4"><ce:initials>F.A.</ce:initials><ce:indexed-name>Ross F.A.</ce:indexed-name><ce:surname>Ross</ce:surname></author><author seq="5"><ce:initials>S.A.</ce:initials><ce:indexed-name>Hawley S.A.</ce:indexed-name><ce:surname>Hawley</ce:surname></author><author seq="6"><ce:initials>D.G.</ce:initials><ce:indexed-name>Hardie D.G.</ce:indexed-name><ce:surname>Hardie</ce:surname></author></ref-authors><ref-sourcetitle>Diabetes</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="64"/><pagerange first="360" last="369"/></ref-volisspag></ref-info><ref-fulltext>S.Pirkmajer, S.S.Kulkarni, R.Z.Tom, F.A.Ross, S.A.Hawley, D.G.Hardie, et al. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. Diabetes 2015;64:360–9.</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Methotrexate increases skeletal muscle GLUT4 expression and improves metabolic control in experimental diabetes</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84873848622</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.T.</ce:initials><ce:indexed-name>Russo G.T.</ce:indexed-name><ce:surname>Russo</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Minutoli L.</ce:indexed-name><ce:surname>Minutoli</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Bitto A.</ce:indexed-name><ce:surname>Bitto</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Altavilla D.</ce:indexed-name><ce:surname>Altavilla</ce:surname></author><author seq="5"><ce:initials>E.</ce:initials><ce:indexed-name>Alessi E.</ce:indexed-name><ce:surname>Alessi</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Giandalia A.</ce:indexed-name><ce:surname>Giandalia</ce:surname></author></ref-authors><ref-sourcetitle>J Nutr Metab</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="2012"/><pagerange first="132056"/></ref-volisspag></ref-info><ref-fulltext>G.T.Russo, L.Minutoli, A.Bitto, D.Altavilla, E.Alessi, A.Giandalia, et al. Methotrexate increases skeletal muscle GLUT4 expression and improves metabolic control in experimental diabetes. J Nutr Metab 2012;2012:132056.</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Polyglutamation of methotrexate. Is methotrexate a prodrug?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0022410582</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.A.</ce:initials><ce:indexed-name>Chabner B.A.</ce:indexed-name><ce:surname>Chabner</ce:surname></author><author seq="2"><ce:initials>C.J.</ce:initials><ce:indexed-name>Allegra C.J.</ce:indexed-name><ce:surname>Allegra</ce:surname></author><author seq="3"><ce:initials>G.A.</ce:initials><ce:indexed-name>Curt G.A.</ce:indexed-name><ce:surname>Curt</ce:surname></author><author seq="4"><ce:initials>N.J.</ce:initials><ce:indexed-name>Clendeninn N.J.</ce:indexed-name><ce:surname>Clendeninn</ce:surname></author><author seq="5"><ce:initials>J.</ce:initials><ce:indexed-name>Baram J.</ce:indexed-name><ce:surname>Baram</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Koizumi S.</ce:indexed-name><ce:surname>Koizumi</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Invest</ref-sourcetitle><ref-publicationyear first="1985"/><ref-volisspag><voliss volume="76"/><pagerange first="907" last="912"/></ref-volisspag></ref-info><ref-fulltext>B.A.Chabner, C.J.Allegra, G.A.Curt, N.J.Clendeninn, J.Baram, S.Koizumi, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907–12.</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5ʹ-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0022637441</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.E.</ce:initials><ce:indexed-name>Baggott J.E.</ce:indexed-name><ce:surname>Baggott</ce:surname></author><author seq="2"><ce:initials>W.H.</ce:initials><ce:indexed-name>Vaughn W.H.</ce:indexed-name><ce:surname>Vaughn</ce:surname></author><author seq="3"><ce:initials>B.B.</ce:initials><ce:indexed-name>Hudson B.B.</ce:indexed-name><ce:surname>Hudson</ce:surname></author></ref-authors><ref-sourcetitle>Biochem J</ref-sourcetitle><ref-publicationyear first="1986"/><ref-volisspag><voliss volume="236"/><pagerange first="193" last="200"/></ref-volisspag></ref-info><ref-fulltext>J.E.Baggott, W.H.Vaughn, B.B.Hudson. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5ʹ-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193–200.</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0010105962</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Allegra C.J.</ce:indexed-name><ce:surname>Allegra</ce:surname></author><author seq="2"><ce:initials>J.C.</ce:initials><ce:indexed-name>Drake J.C.</ce:indexed-name><ce:surname>Drake</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Jolivet J.</ce:indexed-name><ce:surname>Jolivet</ce:surname></author><author seq="4"><ce:initials>B.A.</ce:initials><ce:indexed-name>Chabner B.A.</ce:indexed-name><ce:surname>Chabner</ce:surname></author></ref-authors><ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle><ref-publicationyear first="1985"/><ref-volisspag><voliss volume="82"/><pagerange first="4881" last="4885"/></ref-volisspag></ref-info><ref-fulltext>C.J.Allegra, J.C.Drake, J.Jolivet, B.A.Chabner. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985;82:4881–5.</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">2442644204</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Marie S.</ce:indexed-name><ce:surname>Marie</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Heron B.</ce:indexed-name><ce:surname>Heron</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Bitoun P.</ce:indexed-name><ce:surname>Bitoun</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Timmerman T.</ce:indexed-name><ce:surname>Timmerman</ce:surname></author><author seq="5"><ce:initials>G.</ce:initials><ce:indexed-name>Van Den Berghe G.</ce:indexed-name><ce:surname>Van Den Berghe</ce:surname></author><author seq="6"><ce:initials>M.F.</ce:initials><ce:indexed-name>Vincent M.F.</ce:indexed-name><ce:surname>Vincent</ce:surname></author></ref-authors><ref-sourcetitle>Am J Hum Genet</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="74"/><pagerange first="1276" last="1281"/></ref-volisspag></ref-info><ref-fulltext>S.Marie, B.Heron, P.Bitoun, T.Timmerman, G.Van Den Berghe, M.F.Vincent. AICA-ribosiduria:a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am J Hum Genet 2004;74:1276–81.</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Quantification of urinary AICAR concentrations as a matter of doping controls</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77951221074</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Thomas A.</ce:indexed-name><ce:surname>Thomas</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Beuck S.</ce:indexed-name><ce:surname>Beuck</ce:surname></author><author seq="3"><ce:initials>J.C.</ce:initials><ce:indexed-name>Eickhoff J.C.</ce:indexed-name><ce:surname>Eickhoff</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Guddat S.</ce:indexed-name><ce:surname>Guddat</ce:surname></author><author seq="5"><ce:initials>O.</ce:initials><ce:indexed-name>Krug O.</ce:indexed-name><ce:surname>Krug</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Kamber M.</ce:indexed-name><ce:surname>Kamber</ce:surname></author></ref-authors><ref-sourcetitle>Anal Bioanal Chem</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="396"/><pagerange first="2899" last="2908"/></ref-volisspag></ref-info><ref-fulltext>A.Thomas, S.Beuck, J.C.Eickhoff, S.Guddat, O.Krug, M.Kamber, et al. Quantification of urinary AICAR concentrations as a matter of doping controls. Anal Bioanal Chem 2010;396:2899–908.</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">5644235310</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.L.</ce:initials><ce:indexed-name>Morgan S.L.</ce:indexed-name><ce:surname>Morgan</ce:surname></author><author seq="2"><ce:initials>R.A.</ce:initials><ce:indexed-name>Oster R.A.</ce:indexed-name><ce:surname>Oster</ce:surname></author><author seq="3"><ce:initials>J.Y.</ce:initials><ce:indexed-name>Lee J.Y.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="4"><ce:initials>G.S.</ce:initials><ce:indexed-name>Alarcon G.S.</ce:indexed-name><ce:surname>Alarcon</ce:surname></author><author seq="5"><ce:initials>J.E.</ce:initials><ce:indexed-name>Baggott J.E.</ce:indexed-name><ce:surname>Baggott</ce:surname></author></ref-authors><ref-sourcetitle>Arthritis Rheum</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="50"/><pagerange first="3104" last="3111"/></ref-volisspag></ref-info><ref-fulltext>S.L.Morgan, R.A.Oster, J.Y.Lee, G.S.Alarcon, J.E.Baggott. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004;50:3104–11.</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0032802514</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.E.</ce:initials><ce:indexed-name>Baggott J.E.</ce:indexed-name><ce:surname>Baggott</ce:surname></author><author seq="2"><ce:initials>S.L.</ce:initials><ce:indexed-name>Morgan S.L.</ce:indexed-name><ce:surname>Morgan</ce:surname></author><author seq="3"><ce:initials>W.M.</ce:initials><ce:indexed-name>Sams W.M.</ce:indexed-name><ce:surname>Sams</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Linden J.</ce:indexed-name><ce:surname>Linden</ce:surname></author></ref-authors><ref-sourcetitle>Arch Dermatol</ref-sourcetitle><ref-publicationyear first="1999"/><ref-volisspag><voliss volume="135"/><pagerange first="813" last="817"/></ref-volisspag></ref-info><ref-fulltext>J.E.Baggott, S.L.Morgan, W.M.Sams, J.Linden. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999;135:813–17.</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84890124526</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Thomas A.</ce:indexed-name><ce:surname>Thomas</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Vogel M.</ce:indexed-name><ce:surname>Vogel</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Piper T.</ce:indexed-name><ce:surname>Piper</ce:surname></author><author seq="4"><ce:initials>O.</ce:initials><ce:indexed-name>Krug O.</ce:indexed-name><ce:surname>Krug</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Beuck S.</ce:indexed-name><ce:surname>Beuck</ce:surname></author><author seq="6"><ce:initials>W.</ce:initials><ce:indexed-name>Schanzer W.</ce:indexed-name><ce:surname>Schanzer</ce:surname></author></ref-authors><ref-sourcetitle>Anal Bioanal Chem</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="405"/><pagerange first="9703" last="9709"/></ref-volisspag></ref-info><ref-fulltext>A.Thomas, M.Vogel, T.Piper, O.Krug, S.Beuck, W.Schanzer, et al. Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. Anal Bioanal Chem 2013;405:9703–9.</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84923260875</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>den Boer E.</ce:indexed-name><ce:surname>den Boer</ce:surname></author><author seq="2"><ce:initials>M.C.</ce:initials><ce:indexed-name>de Rotte M.C.</ce:indexed-name><ce:surname>de Rotte</ce:surname></author><author seq="3"><ce:initials>S.M.</ce:initials><ce:indexed-name>Pluijm S.M.</ce:indexed-name><ce:surname>Pluijm</ce:surname></author><author seq="4"><ce:initials>S.G.</ce:initials><ce:indexed-name>Heil S.G.</ce:indexed-name><ce:surname>Heil</ce:surname></author><author seq="5"><ce:initials>J.M.</ce:initials><ce:indexed-name>Hazes J.M.</ce:indexed-name><ce:surname>Hazes</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>de Jonge R.</ce:indexed-name><ce:surname>de Jonge</ce:surname></author></ref-authors><ref-sourcetitle>J Rheumatol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="41"/><pagerange first="2167" last="2178"/></ref-volisspag></ref-info><ref-fulltext>E.den Boer, M.C.de Rotte, S.M.Pluijm, S.G.Heil, J.M.Hazes, R.de Jonge. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol 2014;41:2167–78.</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Methotrexate–how does it really work?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77749277178</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.S.</ce:initials><ce:indexed-name>Chan E.S.</ce:indexed-name><ce:surname>Chan</ce:surname></author><author seq="2"><ce:initials>B.N.</ce:initials><ce:indexed-name>Cronstein B.N.</ce:indexed-name><ce:surname>Cronstein</ce:surname></author></ref-authors><ref-sourcetitle>Nat Rev Rheumatol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="6"/><pagerange first="175" last="178"/></ref-volisspag></ref-info><ref-fulltext>E.S.Chan, B.N.Cronstein. Methotrexate–how does it really work? Nat Rev Rheumatol 2010;6:175–8.</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Aminoimidazolecarboxamide excretion in vitamin-B12 and folic-acid deficiencies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0001432177</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.L.</ce:initials><ce:indexed-name>Luhby A.L.</ce:indexed-name><ce:surname>Luhby</ce:surname></author><author seq="2"><ce:initials>J.M.</ce:initials><ce:indexed-name>Cooperman J.M.</ce:indexed-name><ce:surname>Cooperman</ce:surname></author></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="1962"/><ref-volisspag><voliss volume="2"/><pagerange first="1381" last="1382"/></ref-volisspag></ref-info><ref-fulltext>A.L.Luhby, J.M.Cooperman. Aminoimidazolecarboxamide excretion in vitamin-B12 and folic-acid deficiencies. Lancet 1962;2:1381–2.</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Urinary aminoimidazolecarboxamide levels in children with acute leukemia</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0014803387</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Lulenski G.</ce:indexed-name><ce:surname>Lulenski</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Donaldson M.</ce:indexed-name><ce:surname>Donaldson</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Newcombe D.</ce:indexed-name><ce:surname>Newcombe</ce:surname></author></ref-authors><ref-sourcetitle>Pediatrics</ref-sourcetitle><ref-publicationyear first="1970"/><ref-volisspag><voliss volume="45"/><pagerange first="983" last="995"/></ref-volisspag></ref-info><ref-fulltext>G.Lulenski, M.Donaldson, D.Newcombe. Urinary aminoimidazolecarboxamide levels in children with acute leukemia. Pediatrics 1970;45:983–95.</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">55849140884</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.M.</ce:initials><ce:indexed-name>Dalrymple J.M.</ce:indexed-name><ce:surname>Dalrymple</ce:surname></author><author seq="2"><ce:initials>L.K.</ce:initials><ce:indexed-name>Stamp L.K.</ce:indexed-name><ce:surname>Stamp</ce:surname></author><author seq="3"><ce:initials>J.L.</ce:initials><ce:indexed-name>O'Donnell J.L.</ce:indexed-name><ce:surname>O’Donnell</ce:surname></author><author seq="4"><ce:initials>P.T.</ce:initials><ce:indexed-name>Chapman P.T.</ce:indexed-name><ce:surname>Chapman</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Zhang M.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="6"><ce:initials>M.L.</ce:initials><ce:indexed-name>Barclay M.L.</ce:indexed-name><ce:surname>Barclay</ce:surname></author></ref-authors><ref-sourcetitle>Arthritis Rheum</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="58"/><pagerange first="3299" last="3308"/></ref-volisspag></ref-info><ref-fulltext>J.M.Dalrymple, L.K.Stamp, J.L.O’Donnell, P.T.Chapman, M.Zhang, M.L.Barclay. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299–308.</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Lesch-Nyhan syndrome: the synthesis of inosine 5ʹ-phosphate in the hypoxanthine-guanine phosphoribosyltransferase-deficient erythrocyte by alternate biochemical pathways</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0017406467</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.A.</ce:initials><ce:indexed-name>Lowy B.A.</ce:indexed-name><ce:surname>Lowy</ce:surname></author><author seq="2"><ce:initials>M.K.</ce:initials><ce:indexed-name>Williams M.K.</ce:indexed-name><ce:surname>Williams</ce:surname></author></ref-authors><ref-sourcetitle>Pediatr Res</ref-sourcetitle><ref-publicationyear first="1977"/><ref-volisspag><voliss volume="11"/><pagerange first="691" last="694"/></ref-volisspag></ref-info><ref-fulltext>B.A.Lowy, M.K.Williams. Lesch-Nyhan syndrome:the synthesis of inosine 5ʹ-phosphate in the hypoxanthine-guanine phosphoribosyltransferase-deficient erythrocyte by alternate biochemical pathways. Pediatr Res 1977;11:691–4.</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0025863078</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Dixon R.</ce:indexed-name><ce:surname>Dixon</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Gourzis J.</ce:indexed-name><ce:surname>Gourzis</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>McDermott D.</ce:indexed-name><ce:surname>McDermott</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Fujitaki J.</ce:indexed-name><ce:surname>Fujitaki</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Dewland P.</ce:indexed-name><ce:surname>Dewland</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Gruber H.</ce:indexed-name><ce:surname>Gruber</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Pharmacol</ref-sourcetitle><ref-publicationyear first="1991"/><ref-volisspag><voliss volume="31"/><pagerange first="342" last="347"/></ref-volisspag></ref-info><ref-fulltext>R.Dixon, J.Gourzis, D.McDermott, J.Fujitaki, P.Dewland, H.Gruber. AICA-riboside:safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31:342–7.</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0023886769</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.P.</ce:initials><ce:indexed-name>Bokkerink J.P.</ce:indexed-name><ce:surname>Bokkerink</ce:surname></author><author seq="2"><ce:initials>M.A.</ce:initials><ce:indexed-name>Bakker M.A.</ce:indexed-name><ce:surname>Bakker</ce:surname></author><author seq="3"><ce:initials>T.W.</ce:initials><ce:indexed-name>Hulscher T.W.</ce:indexed-name><ce:surname>Hulscher</ce:surname></author><author seq="4"><ce:initials>R.A.</ce:initials><ce:indexed-name>De Abreu R.A.</ce:indexed-name><ce:surname>De Abreu</ce:surname></author><author seq="5"><ce:initials>E.D.</ce:initials><ce:indexed-name>Schretlen E.D.</ce:indexed-name><ce:surname>Schretlen</ce:surname></author></ref-authors><ref-sourcetitle>Biochem Pharmacol</ref-sourcetitle><ref-publicationyear first="1988"/><ref-volisspag><voliss volume="37"/><pagerange first="2321" last="2327"/></ref-volisspag></ref-info><ref-fulltext>J.P.Bokkerink, M.A.Bakker, T.W.Hulscher, R.A.De Abreu, E.D.Schretlen. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 1988;37:2321–7.</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>Diagnosing AICA-ribosiduria by capillary electrophoresis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33749427999</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Hornik P.</ce:indexed-name><ce:surname>Hornik</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Vyskocilova P.</ce:indexed-name><ce:surname>Vyskocilova</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Friedecky D.</ce:indexed-name><ce:surname>Friedecky</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Adam T.</ce:indexed-name><ce:surname>Adam</ce:surname></author></ref-authors><ref-sourcetitle>J Chromatogr B Analyt Technol Biomed Life Sci</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="843"/><pagerange first="15" last="19"/></ref-volisspag></ref-info><ref-fulltext>P.Hornik, P.Vyskocilova, D.Friedecky, T.Adam. Diagnosing AICA-ribosiduria by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2006;843:15–19.</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>